Month: October 2026

Spotlights ibex’s Industry-leading Growth and Culture in the Region

WASHINGTON, Oct. 29, 2026 (GLOBE NEWSWIRE) — ibex (NASDAQ: IBEX), a global leader in outsourced business services and AI-powered customer experience solutions, was recognized as Frost & Sullivan’s 2026 Central America and the Caribbean Customer Experience Management Services Company of the Year. This reflects ibex’s outstanding performance, innovative AI-enabled solutions, and people-first leadership philosophy across its global footprint.

The report also acknowledged ibex’s significant growth in Central America and the Caribbean over the past seven years, including revenue growth of over 150% from 2018 to 2025.

“ibex’s continued innovation, substantial growth in Central America and the Caribbean region, and its highly rated client engagements make it the clear choice for CX Company of the Year,” said Sebastian Menutti, industry director at Frost & Sullivan. “With its leadership position in deploying AI-powered solutions, including AI Agents at scale, ibex has firmly established itself as the benchmark for CX delivery and execution in this region.”

“This recognition belongs to our teams across Central America and the Caribbean who deliver exceptional experiences for our customers every day,” said Bob Dechant, CEO of ibex. “It’s a testament to our growth and confirms what we’ve always believed: the companies that will win in customer experience are those that seamlessly combine the power of AI with human connection across the end-to-end customer journey.”

Frost & Sullivan’s Company of the Year recognition is powered by its Best Practices Criteria: a rigorous analytical process that involves a detailed evaluation across two dimensions for each nominated company. ibex was measured by Visionary Innovation & Performance and Customer Impact, excelling in both categories.

“The Central America and Caribbean region is a highly competitive talent market for customer service professionals, and our award-winning culture and employee development and growth opportunities help differentiate ibex from the pack,” said David Afdahl, Chief Operating Officer at ibex. “We’re proud of our consistent growth and industry-best employee Net Promoter Score of 82 and delighted to be recognized as the CX leader in this key region.”

With growing operations in Nicaragua, Honduras, and Jamaica, ibex continues to strengthen its position as the business process outsourcing leader and employer of choice in the region. ibex was also recently ranked in the Top 10 Best Places to Work for Service Professionals in the Caribbean and Central America by Great Place to Work^®, and remains committed to investing in its people, driving innovation, and creating meaningful opportunities for professional growth.

About ibex

ibex is a global leader in outsourced business services and AI-powered customer experience solutions, enabling the world’s best brands to deliver truly differentiated experiences for their customers. Leveraging a global team of more than 40,000 human CX experts – powered by the best AI technology, decades of CX innovation, and deep business insights – ibex engineers seamless, end-to-end customer journeys from AI agents to human agents at scale across retail, e-commerce, healthcare, fintech, utilities, technology, logistics, and more. Discover more at ibex.co and connect with us on LinkedIn.

Media Contact
Dan Burris
ibex
Daniel.Burris@ibex.co

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99bb7ba1-0f73-4f22-af62-7e5790e4e745

Oral presentation: November 20, 2026 at 15:00 CET

REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tri-specific antibody from its CAPTN-3 platform, for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain, on November 18-20, 2026.

Data evaluating IM1240 in treatment-resistant human tumor models, including its multi-arm mechanism of action and the contribution of NKG2A engagement, as well as pharmacokinetic and safety evaluation of CAPTN-3’s conditional CD3 masking approach, will be presented in a plenary session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai.

“We are pleased that our IM1240 abstract has been selected for a plenary session oral presentation at the EORTC-NCI-AACR Symposium,” said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. “We are excited with the progress made in our latest work on the CAPTN-3 platform and its lead candidate IM1240 and we look forward to completing our IND-enabling work and, subject to regulatory clearance, initiating our planned first-in-human clinical study for IM1240 in 2027.”

Presentation:

Title: Conditionally activated NKG2A-engaging tri-specific antibody remodels IO-resistant human tumor microenvironments with improved tumor killing and pharmacologic safety
Session Title: Plenary Session 7: Proffered Papers
Abstract Number: ENA26-0137
Presenter: Amir Horowitz, Ph.D., Icahn School of Medicine at Mount Sinai
Date and Time: Friday, November 20, 2026, at 15:00 CET

The presentation is planned to be available on the Purple Biotech website following the presentation at the symposium.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company is focused on advancing CAPTN-3 – a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Capping technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers. The platform’s lead candidate, IM1240, is advancing toward the clinic, and its second candidate, IM1305, is in preclinical development. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for CAPTN-3; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; our ability to raise additional capital on acceptable terms, or at all, to fund our research and development activities, including preclinical and clinical studies; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2025 as such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission (“SEC”), including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, https://www.sec.gov.

CONTACTS:

Company Contact:
IR@purple-biotech.com

FAIRFAX, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) — WidePoint Corporation (NYSE American: WYY), a leading provider of Secure Mobility Management and Managed Services Solutions, will hold a conference call on Thursday, November 12, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2026. Financial results will be issued in a press release prior to the call.

WidePoint’s management will host the conference call, followed by a question and answer period.

Date: Thursday, November 12, 2026
Time: 4:30 p.m. ET (1:30 p.m. PT)
U.S. dial-in number: 888-506-0062
International number: 973-528-0011
Access Code: 633294

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at (949) 574-3860.

The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website. A replay of the conference call will be available after 7:30 p.m. ET on the same day through Thursday, November 26, 2026.

Toll-free replay number: 877-481-4010
International replay number: 919-882-2331
Replay ID: 54625

About WidePoint
WidePoint Corporation (NYSE American: WYY) is a leading technology Managed Solution Provider (MSP) dedicated to securing and protecting the mobile workforce and enterprise landscape. WidePoint is recognized for pioneering technology solutions that include Identity & Access Management (IAM), Mobility Managed Services (MMS), Telecom Management, Information Technology as a Service, Cloud Security, and Analytics & Billing as a Service (ABaaS). To learn more, visit https://www.widepoint.com. 

WidePoint Investor Relations:
Gateway Group, Inc.
Matt Glover or John Yi
949-574-3860
WYY@gateway-grp.com

Nonclinical studies demonstrated reductions in two key measures of neuropathic pain

Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13’s potential to address multiple cancer-related symptoms

SOLANA BEACH, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced that it will present data demonstrating the potential of ART27.13 to treat chemotherapy-induced neuropathic pain at the IASP 2026 World Congress on Pain, taking place October 26–30, 2026, in Bangkok, Thailand.

Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, will deliver a presentation today entitled “88: Effects of ART27.13 in a Preclinical Model of Paclitaxel-Induced Peripheral Neuropathy.”

ART27.13, a once-daily oral, peripherally selective CB1 and CB2 receptor agonist, is currently in Phase 2 clinical development for cancer-related anorexia and weight loss. The findings highlight its potential to address chemotherapy-induced neuropathic pain, expanding its possible applications in cancer supportive care.

ART27.13 – Exploring New Potential in Chemotherapy-Induced Neuropathic Pain

• Significant unmet need: Chemotherapy-induced peripheral neuropathy affects approximately 60% to 80% of patients receiving paclitaxel, highlighting the need for effective pain management alternatives.
• Encouraging pain data: In a nonclinical model of paclitaxel-induced peripheral neuropathy, repeated dosing with ART27.13 reduced sensitivity to touch (mechanical allodynia) and heat (thermal hyperalgesia) in both male and female animals.
• Ongoing clinical evaluation: Artelo has incorporated multiple pain endpoints into its ongoing Phase 2 Cancer Appetite Recovery Study (CAReS) to assess whether the analgesic effects observed in nonclinical studies translate to patients with cancer.
• Broader therapeutic potential: ART27.13 may offer a single, once-daily oral treatment addressing multiple cancer-related symptoms, including appetite loss, weight loss and neuropathic pain.

“Cancer patients frequently experience multiple debilitating symptoms, including appetite loss, weight loss and neuropathic pain, yet treatment options remain limited,” said Professor O’Sullivan. “Our nonclinical findings demonstrate ART27.13’s potential to reduce chemotherapy-induced neuropathic pain, complementing the encouraging weight gain and activity improvements observed from our Phase 2 CAReS trial’s interim analysis. Importantly, the trial already includes pain endpoints, providing an opportunity once CAReS is completed to evaluate whether ART27.13 could address multiple cancer-related symptoms through a single, once-daily oral therapy.”

Organized by the International Association for the Study of Pain (IASP), the World Congress on Pain is the largest global gathering of pain professionals, bringing together thousands of scientists, clinicians and healthcare providers from around the world.

About ART27.13

Initially developed by AstraZeneca plc, ART27.13 is a dual cannabinoid agonist that has been evaluated in six clinical studies and two ongoing clinical trials with nearly 300 participants. It is being developed as a once-daily oral agent that selectively targets peripheral CB1 and CB2 receptors, enabling systemic metabolic effects while minimizing central nervous system-mediated toxicity.

Artelo is conducting a Phase 2 trial, the Cancer Appetite Recovery Study (CAReS), evaluating ART27.13 as a supportive care therapy for cancer patients with anorexia and weight loss. Patients had to have lost at least 5% of body weight to enroll. In interim data, those titrated to the highest dose (1300 µg) gained an average of 6% of body weight over 12 weeks, while patients on placebo lost an additional ~5%. There is currently no FDA-approved treatment for cancer anorexia cachexia syndrome. ART27.13 is also being evaluated in DREAM, a Phase 2 study in people with glaucoma investigating whether oral daily treatment can lower intraocular pressure.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in obesity, anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth or partnering opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including but not limited to: our ability to raise additional capital in the future; the inherent uncertainties of preclinical and clinical research, including the possibility that results observed in nonclinical animal models may not be predictive of, or replicated in, human clinical trials; the uncertainty of patent protection and the potential for intellectual property challenges; the highly competitive nature of the pharmaceutical industry; the risk that third-party market projections may not materialize or that the Company may not be able to participate in projected market opportunities; the timing, content and availability of the Company’s presentations at the IASP 2026 World Congress on Pain; and our ability to enter into partnering or licensing arrangements on acceptable terms, or at all. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ARTL@crescendo-ir.com

New Global Insights Report finds accuracy and effectiveness among marketers’ top priorities when evaluating AI solutions

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — DoubleVerify (“DV”) (NYSE: DV), the leading software platform to verify media quality, optimize ad performance and prove campaign outcomes, today released new findings from its 2026 Global Insights Report, Beyond the Hype: The Real State of AI in Digital Advertising, revealing that 97% of marketers plan to use AI across some aspects of media planning, buying and optimization in 2026. However, the findings reveal that broad plans to use AI have yet to translate into equally widespread adoption across individual advertising workflows. Drawing on a global survey of 2,020 marketers and additional DV data, the report examines where AI is gaining traction, as well as the priorities and concerns shaping marketers’ evaluation of AI solutions.

“AI is becoming a part of how nearly every marketer plans and buys media, but when you look at adoption across individual workflows, the picture is more nuanced,” said Mark Zagorski, CEO, DV. “Marketers are increasingly embracing AI, but there’s still considerable opportunity to integrate it more deeply into each step of how campaigns are planned, bought and optimized.”

Key report findings include:

• More marketers are using AI to develop media briefs: AI adoption for summarizing media briefs increased from 28% in 2024 to 37% in 2025, with usage expected to reach 40% in 2026.
• AI is gaining ground in campaign activation and bidding: In 2025, 35% of marketers used AI to activate campaigns, up from 31% in 2024, while 29% used it to optimize bidding, up from 24%. Usage is expected to reach 40% and 34%, respectively, in 2026.
• AI adoption for mid-flight optimization is accelerating: The percentage of marketers using AI to optimize campaigns mid-flight (adjusting campaigns while live) increased by 10 percentage points, from 21% in 2024 to 31% in 2025, with usage expected to reach 36% in 2026.

Despite uneven adoption across individual workflows, AI-powered bidding is delivering promising results: 98% of marketers using these solutions reported performance improvements, according to DV’s research.

Accuracy and Effectiveness Lead Marketers’ AI Priorities

As AI takes on a greater role in advertising operations, marketers are placing significant emphasis on the quality, reliability and value of the solutions they adopt. When evaluating AI optimization offerings, marketers prioritize:

• Accuracy and effectiveness of AI recommendations and optimization (35%), the most frequently cited consideration.
• Data privacy and security compliance (29%), reflecting the importance of protecting sensitive information as AI becomes more integrated into advertising operations.
• Cost and return on investment (29%), highlighting the need to demonstrate tangible business value from AI investments.

“Today’s AI optimization solutions are already helping marketers make smarter decisions and improve campaign performance,” added Zagorski. “As these capabilities advance, we expect AI agents to take on a greater role in managing campaign optimization on behalf of advertisers. That creates significant opportunity, but it also raises the stakes for accuracy, transparency and measurable performance. Marketers need to trust not only the recommendations AI makes, but also the actions it takes.”

DV helps advertisers automate and optimize campaign performance through DV Scibids AI^™, which uses first-party data and trusted third-party measurement inputs to generate custom bidding algorithms aligned with campaign KPIs. The technology helps improve campaign outcomes while reducing the need for manual optimization. DV Scibids AI is part of DV’s Media AdVantage Platform (DV MAP^™), which brings together media verification, AI-powered optimization and outcomes measurement to help advertisers improve media effectiveness and return on ad spend.

The full 2026 Global Insights Report: Beyond the Hype: The Real State of AI in Digital Advertising is available for download here.

About DV
DoubleVerify (“DV”) (NYSE: DV) is the industry’s leading media effectiveness platform that leverages AI to drive superior outcomes for global brands. By creating more effective, transparent ad transactions, DV strengthens the digital advertising ecosystem, ensuring a fair value exchange between buyers and sellers of digital media. For more information about DV, visit http://www.doubleverify.com.

Chris Harihar 
646-535-9475 
chris@crenshawcomm.com 

SurgePays expands GrowthLine into the rural broadband market, with iPMobile expected to bring more than 15 providers onto the platform over the next 12 months

GrowthLine partnership with iPMobile expected to serve hundreds of thousands of customers over time

BARTLETT, Tenn., Oct. 29, 2026 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG) (“SurgePays” or the “Company”), a fintech company that launches and runs wireless brands, today announced a definitive agreement with IP Mobile, LLC (“iPMobile”) to bring rural broadband providers onto GrowthLine by SurgePays. The partnership enables participating broadband providers to offer wireless service to their existing customers under their own brands, with SurgePays providing the complete wireless operation.

iPMobile will serve as SurgePays’ exclusive rural broadband sales channel partner, recruiting providers and securing agreements for their branded wireless offerings. SurgePays will serve as iPMobile’s exclusive wireless platform partner, providing carrier access, technology, activation, billing and payments, customer care, compliance and daily operations through its GrowthLine platform.

“We intend to move aggressively and with a custom-tailored solution for smaller size wireless internet service providers (WISP) to large fiber providers and everyone in between. We are not just connecting to 5G services, but providing a full white label, white glove service led by SurgePays’ development and technology team and a full go to market plan and strategy supported by iPMobile. We expect to bring more than 15 rural broadband brands onto GrowthLine over the next 12 months and build this partnership into a wireless business serving hundreds of thousands of customers,” said Brett Wantland, Vice President of iPMobile. “These providers have already earned a place in their customers’ homes. Our opportunity is to help them win the wireless business, too. We believe SurgePays’ GrowthLine platform is the perfect solution for any broadband company, big or small. The wireless industry is changing, and broadband companies want to stay ahead of the curve, protect their existing base, and serve more of their needs. With our combined 60+ years in telecom, we know this isn’t as easy as getting connected. Our broadband providers need a partner that can guide them through the entire process, from start to finish and beyond. We see this as a major growth channel to deliver that solution while offering a seamless and integrated billing platform.”

“With the launch of GrowthLine, we expanded how SurgePays grows, offering partners access to our entire infrastructure, including 24/7 live support. We believe we have built not only the most innovative platform but also the only platform that encompasses every aspect of a wireless operation. For partners seeking to launch their own wireless brands, we have made the process fast, simple, and profitable. This partnership with iPMobile further validates that approach and gives us a direct pipeline to rural broadband providers that have already built customer relationships. Each provider iPMobile brings onto GrowthLine can sell wireless service to its existing customers, adding subscribers to infrastructure we have already built. That operating leverage is how we plan to build value for the Company,” said Brian Cox, Chief Executive Officer of SurgePays.

“Rural broadband companies already have the customer relationships. This partnership gives them another service to sell to those customers, a new source of recurring revenue, and a way to defend those customers against emerging companies that offer broadband and wireless together,” said Allison Seyler, Vice President of Sales at SurgePays. “iPMobile brings the sales channel, the broadband companies bring their brands and customers, and GrowthLine provides the wireless operation.”

The program lets broadband providers expand their service offerings while keeping their own customer-facing brands. Each participating provider will receive a negotiated share of margin after direct costs. iPMobile will manage provider recruitment and commercial relationships, while SurgePays operates the wireless service and back office.

About SurgePays, Inc.

SurgePays, Inc. (NASDAQ: SURG) is a fintech company that launches and runs wireless brands. Through its GrowthLine platform, SurgePays provides partners with carrier access, technology, payments, customer care, compliance and daily operations from platforms it developed and an operations center and NOC it runs. The Company also owns LinkUp Mobile, its own prepaid wireless brand, and operates SurgePays POS, which handles retail sales and payments for wireless companies at neighborhood stores. SurgePays brings affordable wireless service and prepaid financial products to consumers through partners and neighborhood stores. For more information, please visit www.surgepays.com.

About iPMobile

iPMobile helps rural and regional Internet Service Providers launch and grow their own wireless offerings, from carrier connectivity and devices to strategy, marketing, operations, and ongoing optimization. For more information, please visit www.ipmobile.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth of the iPMobile partnership, the expectation that more than 15 rural broadband brands will join GrowthLine over the next 12 months, the expectation that the partnership will serve hundreds of thousands of wireless customers over time, the timing of partner brand launches, customer adoption, recurring revenue, margins, operating leverage and the future performance of the Company. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, and actual results could differ materially from those expressed or implied. The brand and customer expectations described in this release are not commitments from broadband providers or customers, and there can be no assurance that these expectations will be achieved or that partner brands will launch on anticipated timelines. Factors that could cause actual results to differ materially include, among others, the ability to recruit and onboard broadband providers, customer conversion and retention, the Company’s dependence on carrier and payment relationships, partner performance, regulatory developments affecting wireless and payment services, competition, and the risks and uncertainties described in the filings of the Company with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. SurgePays undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor Relations Contact

SurgePays, Inc.
ir@surgepays.com

• Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer
• Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach

BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer’s (“SITC”) Annual Meeting. The meeting will take place November 4-8, 2026 in Phoenix, Arizona.

Presentation Details:

Keynote/Plenary Session

Title: Updates on Clinical Results from the AMPLIFY-7P Study of a Lymph Node-Targeted KRAS Vaccine
Presenter: Darrell J. Irvine, PhD, The Scripps Research Institute
Session Number/Name: 103: Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future
Presentation Date/Time: Friday, November 6, 2026, at 10:04 am MT
Location: Phoenix Convention Center – North Building – 300 Level – Halls BC

Late-Breaking Abstract Poster Presentation

Title: Seven valent mKRAS lymph node targeted amphiphile vaccine drives mKRAS-specific T cell responses that correlate with improved clinical outcomes in the AMPLIFY-7P randomized phase 2 trial
Presenter: Christopher M. Haqq
Abstract Number: 1186
Session Date/Time: Saturday, November 7, 2026, 12:30-1:30 pm MT and 6:40-8:10 pm MT
Location: Phoenix Convention Center – North Building -Lower Level – Exhibition Halls 4-6

Poster Presentation

Title: Direct intratumoral delivery of amphiphilic immunomodulators induces durable anti-tumor efficacy
Presenter: Martin Steinbuck
Abstract Number: 824
Session Date/Time: Saturday, November 7, 2026, at 12:30-1:30pm MT and 6:40-8:10pm MT
Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4-6

About the AMPLIFY-7P Phase 2 Study

AMPLIFY-7P Phase 2 is a randomized study evaluating camupepimut (ELI-002 7P) versus observation in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma following completion of standard locoregional therapy. The study enrolled 144 patients across 24 U.S. clinical sites.

About camupepimut (ELI-002 7P)

Camupepimut is an investigational, off-the-shelf immunotherapy designed to generate immune responses against seven of the most common KRAS mutations. Camupepimut utilizes Elicio’s proprietary Amphiphile (“AMP”) technology to target mutant KRAS peptide antigens and an immune-stimulatory adjuvant directly to the lymph nodes, where adaptive immune responses are orchestrated.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies.

Elicio’s AMP technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s camupepimut lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors.

Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing and rapid availability of drug to patients, especially in neoadjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches.

Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively.

For more information, please visit www.elicio.com.

Cautionary Note on Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA.

These include statements regarding the timing and content of Elicio’s presentation at SITC 2026 Annual Meeting; the clinical activity, therapeutic potential and potential benefits of camupepimut (ELI-002 7P); the interpretation and potential implications of results and analyses from Elicio’s preclinical studies; the interpretation and potential implications of results and analyses from Elicio’s AMPLIFY-7P study, including the observation that mKRAS-specific T cell responses correlate with improved clinical outcomes; Elicio’s planned clinical programs, including planned clinical trials; the potential of Elicio’s product candidates and platform; the potential for pre-specified analyses to further characterize the clinical activity of camupepimut (ELI-002 7P); the potential benefits and effectiveness of off-the-shelf immunotherapy approaches; the potential participation and presentation at upcoming conferences and medical meetings; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them.

No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.

Elicio uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

Such forward-looking statements are based on Elicio’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s plans to develop and commercialize its product candidates, including camupepimut; the timing of initiation of Elicio’s planned clinical trials; the timing of the availability and presentation of data from Elicio’s clinical trials; the design and timing of future clinical trials; the timing of any planned investigational new drug application or new drug application; Elicio’s plans to research, develop and commercialize its current and future product candidates; and Elicio’s estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time to time, and it is not possible for Elicio to predict all such factors, nor can Elicio assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

These risks are more fully discussed under the heading “Risk Factors” in Elicio’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as amended on April 29, 2026, Elicio’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 11, 2026, and Elicio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026, as updated by subsequent reports and other documents filed from time to time with the SEC.

Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.

Elicio Investor Relations Contact

Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

Always-on neuromorphic AI with on-chip learning comes to the world’s most popular single-board computer

LAGUNA HILLS, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), a global leader in ultra-low-power, fully digital, event-based neuromorphic AI, today launched the AKD1500 Raspberry Pi 5 Development Kit. The kit pairs a Raspberry Pi 5 with BrainChip’s AKD1500 M.2 board, giving the millions of engineers, makers and product teams who already build on Raspberry Pi an off-the-shelf way to develop low-power, always-on AI applications – and a clear path to production on the same AKD1500 chip.

“As an American Tier 1 for physical AI, Hellbender looks for edge technologies that can move cleanly from prototype to production,” said Brian Beyer, CEO, Hellbender. “BrainChip’s AKD1500 Raspberry Pi 5 kit makes it easy for engineering teams to evaluate low-power, always-on AI on familiar hardware, and we see it as a promising option for the robotics and vision applications our customers are building.”

The challenge: always-on AI strains power, privacy and the path to production

A growing class of edge devices – sensors, monitors, wearables, industrial equipment and smart home products – must listen, watch or measure continuously. Running AI on these devices with conventional processors means analyzing every frame and sample, whether anything has changed, which drains batteries and adds heat. Sending the data to the cloud instead adds latency, bandwidth cost and privacy risk. And once a model is deployed, teaching it something new typically means collecting data, retraining in the cloud and pushing an update.

Developers face a second hurdle: the hardware used to build a proof of concept is often not the hardware that ships. Moving from a prototype to a production design can mean re-porting models, re-validating performance and starting over on a new platform.

The solution: event-based AI that learns on the device

AKD1500 uses BrainChip’s event-based, neuromorphic architecture to process only meaningful events rather than every piece of incoming data, making it well suited to power always-on workloads such as sensing, monitoring and detection. All processing happens on the device, so applications avoid the latency, bandwidth cost and privacy exposure of the cloud.

AKD1500 also supports on-chip learning, so models can learn new classes directly on the device without cloud retraining. A developer can teach a Raspberry Pi 5 application to recognize a new keyword, gesture or object in the field, and the data stays local.

“Raspberry Pi is where many edge AI products begin,” said Steve Brightfield, chief product officer, BrainChip. “This kit puts neuromorphic AI where developers already work and gives teams a fast, low-cost way to validate applications on streaming data.”

“Kit support will include Docker images that can be preloaded to simplify benchmarking and demos and that serve as a reference for custom neuromorphic application containers. Developers who already have a Raspberry Pi 5 with an M.2 HAT can add the production AKD1500 M.2 card and use the same software.”

From prototype to production on one chip

The kit is off the shelf and quick to set up. Teams evaluate their application on Raspberry Pi 5, then design the same AKD1500 chip into their own product with a PCIe or SPI interface to suit their system without switching to new silicon. The kit joins the AKD1500 PCIe card and AKD1500 M.2 board in BrainChip’s family of AKD1500 development platforms, and teams can prototype on any of them.

For developers, the kit offers:

• A familiar platform: Build and test edge AI on Raspberry Pi 5 hardware and workflows developers already know.
• Always-on efficiency: Event-based processing handles continuous sensing workloads without processing every input.
• Local learning and privacy: Add new keywords, gestures or objects on the device, with no cloud retraining and no data leaving the device.
• Free tools and models: BrainChip’s MetaTF software tools and models are available at no charge through the BrainChip Developer Hub.
• One chip, prototype to product: The AKD1500 chip that runs on the kit is the same one teams design into production.

Strategic significance for BrainChip

According to MarketsandMarkets, the global edge computing market is projected to grow from $111.34 billion in 2026 to $317.39 billion by 2031, fueled by organizations prioritizing faster data processing, low-latency applications and decentralized digital infrastructure.

The AKD1500 Raspberry Pi 5 Development Kit reflects BrainChip’s commitment to executing its product roadmap and delivering the production-ready tools developers need today. It advances three priorities:

• Broader developer adoption: Putting Akida in front of the Raspberry Pi community expands the pipeline of engineers who design with Akida.
• AKD1500 commercialization: Alongside the PCIe card and M.2 board, the kit completes an accessible lineup built on one chip, covering prototyping through production and creating a direct path from evaluation to chip design-ins.
• Edge AI leadership: AKD1500 brings BrainChip’s event-based processing and on-chip learning to a mainstream developer platform.

Availability

The AKD1500 Raspberry Pi 5 Development Kit is available now through the BrainChip Shop. MetaTF software tools and models are available at no charge through the BrainChip Developer Hub.

About BrainChip Holdings Ltd.

BrainChip is the worldwide leader in edge AI on-chip processing and learning. The company’s first-to-market, fully digital, event-based AI processor, Akida™, uses neuromorphic principles to analyze only essential sensor inputs at the point of acquisition, processing data with unmatched efficiency, precision and energy economy. BrainChip’s Sequora™ is an efficient digital AI processor for GenAI and other large models using state-space architectures. BrainChip’s technology is deployed across industries including aerospace, defense, industrial IoT, healthcare, consumer devices, and wearables. Explore more at www.brainchip.com.

Follow BrainChip:

X: https://www.twitter.com/BrainChip_inc

LinkedIn: https://www.linkedin.com/company/7792006

Investor Contact

IR@brainchip.com

Media Contact

Maddie Coe

PRforBrainchip@bospar.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7574c999-bb99-4b7c-881d-77f6488b0a75

MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) — Nortech Systems Incorporated (Nasdaq: NSYS), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical imaging, medical device, aerospace & defense and industrial markets, will hold a live conference call and webcast at 3:30 p.m. Central Time on Thursday, November 12, 2026, to discuss the Company’s third quarter 2026 financial results. The call will be hosted by Jay D. Miller, Chief Executive Officer and President, and Andrew D. C. LaFrence, Chief Financial Officer. To access the live audio conference call, US participants may call 888-506-0062 and international participants may call 973-528-0011. Participant Access Code: 124682. Participants may also access the call via webcast at: https://www.webcaster5.com/Webcast/Page/2814/54544.

###

About Nortech Systems Incorporated 

Nortech Systems Incorporated (“Nortech”) is a leading provider of design and manufacturing solutions for complex electromedical devices, electromechanical systems, assemblies, and components. Nortech primarily serves the medical device, medical imaging, aerospace & defense, and industrial markets. Its design services span concept development to commercial design, and include medical device, software, electrical, mechanical, and biomedical engineering. Its manufacturing and supply chain capabilities are vertically integrated around wire/cable/interconnect assemblies, printed circuit board assemblies, as well as system-level assembly, integration, and final test. Headquartered in Maple Grove, MN, Nortech currently has six manufacturing locations and design centers across the U.S., Latin America, and Asia. Nortech is traded on the NASDAQ Stock Market under the symbol NSYS. Nortech’s website is www.nortechsys.com.

Contact
Andrew D. C. LaFrence
Chief Financial Officer and Senior Vice President of Finance
alafrence@nortechsys.com
952-345-2243

NASHVILLE, Tenn., Oct. 29, 2026 (GLOBE NEWSWIRE) — Truxton Corporation, the parent company of Truxton Trust Company (“Truxton” or “the Bank”) and its subsidiaries, announced its operating results for the quarter ended September 30, 2026. Third-quarter net income attributable to common shareholders was $7.86 million, or $0.68 per diluted share, compared to $5.63 million, or $0.49 per diluted share, for the same quarter in 2025. Truxton completed a 4-for-1 stock split on August 28, 2026. Accordingly, all share and per share data in current and comparable periods have been adjusted to reflect the split.

Key Highlights

• Non-interest income was $7.1 million in the third quarter of 2026, which was $395 thousand higher than the second quarter of 2026 and $1.08 million higher than the third quarter of 2025. Wealth revenue in the third quarter of 2026 was $6.6 million, up 6% from $6.2 million in the prior quarter and up 17% from $5.6 million in the same period in the prior year.
• Net interest income, pre-provision, was $10.1 million in the third quarter and second quarter of 2026 and was up 15% from $8.8 million in the third quarter of 2025.
• The purchase of a renewable energy tax credit for the 2022, 2023 and 2025 tax years benefited net income by approximately $645 thousand in the quarter ended September 30, 2026, by lowering tax expense.
• Loans decreased 1% to $799 million at quarter end compared to $804 million at June 30, 2026, and were up 11% compared to $720 million at September 30, 2025. Quarterly average loan balances were $803 million for the third quarter and second quarter of 2026 and up 14% from $704 million in the third quarter of 2025.
• Total deposits remained the same from June 30, 2026 to September 30, 2026 at $1.12 billion, and were 3% lower in comparison to $1.16 billion at September 30, 2025. This decline was caused by a decrease of $81 million in wholesale deposits from September 30, 2025 to September 30, 2026.
• Net interest margin for the third quarter of 2026 was 3.13%, an increase of 3 basis points from the 3.10% experienced in the quarter ended June 30, 2026, and an increase of 31 basis points from the 2.82% recorded in the quarter ended September 30, 2025. Cost of funds was 2.79% in the third quarter of 2026, up from 2.76% for the quarter ended June 30, 2026, and down from 3.08% for the quarter ended September 30, 2025.
• Asset quality remains sound at Truxton. The Bank had $96 thousand of non-performing assets at September 30, 2026, compared to $141 thousand at June 30, 2026, and $97 thousand at September 30, 2025.
• Allowance for credit losses on loans, excluding that for unfunded commitments, was $7.3 million at quarter end September 30, 2026, compared to $7.4 million at June 30, 2026, and $7.0 million at September 30, 2025. For those three periods, such allowance amounts were 0.92%, 0.92%, and 0.98% of gross loans outstanding at the respective period end. For the same three periods, the Bank’s allowance for unfunded commitments was $797 thousand, $814 thousand, and $650 thousand, respectively.
• The Bank’s capital position remains strong. Its Tier 1 leverage ratio was 9.66% at September 30, 2026, compared to 9.27% at June 30, 2026, and 8.90% at September 30, 2025. Book value per common share was $10.62, $10.78, and $9.63 at September 30, 2026, June 30, 2026, and September 30, 2025, respectively.
• During the three months ended September 30, 2026, Truxton Corporation paid dividends of $0.22 per common share, and repurchased 20,324 shares of its common stock for $519 thousand in the aggregate, or an average price of $25.51 per share.

About Truxton
Truxton is a premier provider of wealth, banking, and family office services for wealthy individuals, their families, and their business interests. Serving clients across the world, Truxton’s vastly experienced team of professionals provides customized solutions to its clients’ complex financial needs. Founded in 2004 in Nashville, Tennessee, Truxton upholds its original guiding principle: do the right thing. Truxton Trust Company is a subsidiary of financial holding company, Truxton Corporation (OTCID: TRUX). For more information, visit truxtontrust.com.

Investor Relations Austin Branstetter 615-250-0783 austin.branstetter@truxtontrust.com

Media Relations Swan Burrus 615-250-0773 swan.burrus@truxtontrust.com

Truxton Corporation
Consolidated Balance Sheets
(000’s)
(Unaudited)
		September 30, 2026*			June 30, 2026*			September 30, 2025*
ASSETS
Cash and due from financial institutions		$	5,407		$	5,269		$	4,597
Restricted cash			1,270			400			880
Interest-bearing deposits in other financial institutions			4,031			10,961			12,790
Federal funds sold			1,508			1,500			4,369
Cash and cash equivalents			12,216			18,130			22,636
Available-for-sale securities			485,648			492,163			529,752
Allowance for credit losses on securities			(342	)		(342	)		–
Available-for-sale securities, net			485,306			491,821			529,752
Loans			798,585			803,705			719,842
Allowance for credit losses on loans			(7,323	)		(7,386	)		(7,035	)
Net loans			791,262			796,319			712,807
Bank owned life insurance			17,777			17,619			17,158
Restricted equity securities			6,097			5,994			3,144
Premises and equipment, net			2,525			2,664			3,005
Accrued interest receivable			5,963			5,967			6,035
Deferred tax asset, net			6,822			3,915			4,187
Other assets			22,487			23,990			14,325
Total assets		$	1,350,455		$	1,366,419		$	1,313,049
LIABILITIES AND SHAREHOLDERS’ EQUITY
Deposits
Noninterest-bearing		$	134,705		$	143,625		$	134,017
Interest-bearing			986,455			980,520			1,024,696
Total deposits			1,121,160			1,124,145			1,158,713
Federal funds purchased			2,300			–			–
Federal Home Loan Bank advances			88,000			86,000			31,000
Federal Reserve Bank borrowings			–			16,000			–
Other liabilities			16,476			15,739			12,539
Total liabilities			1,227,936			1,241,884			1,202,252
Shareholders’ equity
Common stock, $0.10 par value			1,153			287			284
Additional paid-in capital			28,760			29,716			29,217
Retained earnings			106,483			101,158			88,524
Accumulated other comprehensive loss			(13,877	)		(6,626	)		(7,228	)
Total shareholders’ equity			122,519			124,535			110,797
Total liabilities and shareholders’ equity		$	1,350,455		$	1,366,419		$	1,313,049
*The information is preliminary, unaudited and based on company data available at the time of presentation.

Truxton Corporation
Consolidated Statements of Net Income
(000’s)
(Unaudited)
		Three Months Ended									Year To Date
		September 30, 2026*			June 30, 2026*			September 30, 2025*			September 30, 2026*			September 30, 2025*
Noninterest income
Wealth management services		$	6,564		$	6,219		$	5,631		$	18,794		$	16,177
Advisory services			42			57			15			114			1,029
Service charges on deposit accounts			89			85			88			265			251
Bank owned life insurance income			157			155			149			464			436
Other			244			185			133			541			645
Total noninterest income			7,096			6,701			6,016			20,178			18,538
Interest income
Loans, including fees			12,664			12,346			11,312			37,463			32,572
Taxable securities			5,291			5,400			5,710			16,218			14,389
Tax-exempt securities			614			607			518			1,816			1,077
Interest-bearing deposits in other financial institutions			181			252			513			637			1,159
Federal funds sold			46			41			41			143			99
Total interest income			18,796			18,646			18,094			56,277			49,296
Interest expense
Deposits			7,868			7,924			8,710			23,733			23,028
Subordinated debentures and other			–			–			189			–			565
Short-term borrowings			71			28			20			108			188
Long-term borrowings			740			632			392			1,838			1,024
Total interest expense			8,679			8,584			9,311			25,679			24,805
Net interest income			10,117			10,062			8,783			30,598			24,491
Provision for credit losses on available-for-sale securities			–			(278	)		–			(278	)		–
Provision for credit losses on loans			(80	)		201			266			(35	)		776
Net interest income after provision for credit losses			10,197			10,139			8,517			30,911			23,715
Total revenue, net			17,293			16,840			14,533			51,089			42,253
Noninterest expense
Compensation and employee benefits			6,196			5,546			5,121			17,619			15,821
Occupancy			341			362			325			1,040			1,012
Furniture and equipment			107			108			107			322			322
Data processing			409			608			519			1,611			1,341
Wealth management processing fees			192			211			211			616			640
Advertising and public relations			46			48			38			135			170
Professional services			248			271			361			756			889
FDIC insurance assessments			225			465			274			1,045			532
Other			557			614			537			1,776			1,439
Total noninterest expense			8,321			8,233			7,493			24,920			22,166
Income before income taxes			8,972			8,607			7,040			26,169			20,087
Income tax expense			1,109			1,731			1,411			4,632			4,086
Net income		$	7,863		$	6,876		$	5,629		$	21,537		$	16,001
Earnings per share**:
Basic		$	0.68		$	0.60		$	0.49		$	1.87		$	1.44
Diluted		$	0.68		$	0.59		$	0.49		$	1.87		$	1.44
*The information is preliminary, unaudited and based on company data available at the time of presentation. **Historical earnings per share is adjusted retrospectively to reflect the 4-for-1 stock split effective August 28, 2026.

Truxton Corporation
Selected Quarterly Financial Data
At Or For The Three Months Ended
(000’s)
(Unaudited)
		September 30, 2026*	June 30, 2026*	September 30, 2025*
Per Common Share Data
Net income attributable to common shareholders, per share:
Basic		$0.68	$0.60	$0.49
Diluted		$0.68	$0.59	$0.49
Book value per common share		$10.62	$10.78	$9.63
Tangible book value per common share		$10.62	$10.78	$9.63
Basic weighted average common shares		11,220,122	11,266,726	11,203,764
Diluted weighted average common shares		11,228,247	11,272,753	11,215,931
Common shares outstanding at period end		11,534,908	11,555,336	11,507,336
Selected Balance Sheet Data
Tangible common equity ratio		9.07%	9.11%	8.44%
Average Loans		$803,068	$803,039	$703,823
Average earning assets (1)		$1,327,804	$1,338,849	$1,279,930
Average total assets		$1,365,948	$1,376,052	$1,309,545
Average shareholders’ equity		$126,897	$122,335	$104,688
Selected Asset Quality Measures
Nonaccrual loans		$84	$87	$97
90+ days past due still accruing		$12	$54	$0
Total nonperforming loans		$96	$141	$97
Total nonperforming assets		$96	$141	$97
Net charge offs (recoveries)		$1	$2	$0
Nonperforming loans to assets		0.01%	0.01%	0.01%
Nonperforming assets to total assets		0.01%	0.01%	0.01%
Nonperforming assets to total loans and other real estate		0.01%	0.02%	0.01%
Allowance for credit losses to total loans		0.92%	0.92%	0.98%
Net charge offs to average loans		0.00%	0.00%	0.00%
Capital Ratios (Bank Subsidiary Only)
Tier 1 leverage		9.66%	9.27%	8.90%
Common equity tier 1		14.54%	14.02%	13.35%
Total risk-based capital		15.44%	14.92%	14.24%
Selected Performance Ratios
Efficiency ratio		48.34%	49.11%	50.63%
Return on average assets		2.28%	2.00%	1.71%
Return on average shareholders’ equity		24.58%	22.54%	21.33%
Return on average tangible common equity		24.58%	22.54%	21.33%
Net interest margin		3.13%	3.10%	2.82%
*The information is preliminary, unaudited and based on company data available at the time of presentation.
(1) Average earning assets is the daily average of earning assets. Earning assets consists of loans, mortgage loans held for sale, federal funds sold, deposits with banks, and investment securities.

Truxton Corporation
Yield Tables
For The Periods Indicated
(000’s)
(Unaudited)
The following table sets forth the amount of our average balances, interest income or interest expense for each category of interest earning assets and interest-bearing liabilities and the average interest rate for interest earning assets and interest-bearing liabilities, net interest spread and net interest margin for the periods indicated below:
		Three Months Ended September 30, 2026*					Three Months Ended June 30, 2026*					Three Months Ended September 30, 2025*
		Average Balances	Rates / Yields (%)	Interest Income / Expense			Average Balances	Rates / Yields (%)	Interest Income / Expense			Average Balances	Rates / Yields (%)	Interest Income / Expense
Earning assets
Loans		$803,068	6.16	$12,460			$803,039	6.04	$12,091			$703,823	6.19	$10,988
Loan fees		$0	0.10	$204			$0	0.13	$255			$0	0.18	$324
Loans, including fees		$803,068	6.26	$12,664			$803,039	6.17	$12,346			$703,823	6.37	$11,312
Taxable securities		$432,504	4.89	$5,291			$436,307	4.95	$5,400			$464,406	4.92	$5,710
Tax-exempt securities		$67,221	5.45	$614			$67,101	5.40	$607			$60,971	5.07	$518
Interest-bearing deposits in other financial institutions		$20,099	3.56	$181			$28,022	3.61	$252			$47,042	4.33	$513
Federal funds sold		$4,912	3.63	$46			$4,380	3.68	$41			$3,688	4.35	$41
Total earning assets		$1,327,804	5.72	$18,796			$1,338,849	5.67	$18,646			$1,279,930	5.70	$18,094
Noninterest earning assets
Allowance for credit losses		($7,751)					($7,944)					($6,749)
Cash and due from financial institutions		$6,656					$5,383					$5,058
Premises and equipment		$2,609					$2,743					$3,094
Accrued interest receivable		$4,577					$4,363					$4,433
Other assets		$46,052					$44,387					$40,883
Unrealized loss on investment securities		($13,999)					($11,729)					($17,104)
Total assets		$1,365,948					$1,376,052					$1,309,545
Interest-bearing liabilities
Interest-bearing demand		$400,561	2.88	$2,904			$384,078	2.82	$2,699			$357,704	3.21	$2,894
Savings and money market		$283,304	2.48	$1,772			$279,119	2.48	$1,729			$261,382	2.74	$1,807
Time deposits – retail		$12,102	3.23	$98			$8,812	3.23	$71			$11,998	3.35	$101
Time deposits – wholesale		$311,638	3.94	$3,094			$356,978	3.85	$3,425			$381,887	4.06	$3,908
Total interest-bearing deposits		$1,007,605	3.10	$7,868			$1,028,987	3.09	$7,924			$1,012,971	3.41	$8,710
Subordinated debentures and other		$0	0.00	$0			$0	0.00	$0			$13,743	5.36	$189
Short-term borrowings		$10,141	2.75	$71			$7,364	1.48	$28			$5,614	4.23	$20
Long-term borrowings		$77,120	3.76	$740			$67,319	3.72	$632			$36,467	4.20	$392
Total borrowed funds		$87,261	3.64	$811			$74,683	3.50	$660			$55,824	4.21	$601
Total interest-bearing liabilities		$1,094,866	3.14	$8,679			$1,103,670	3.12	$8,584			$1,068,795	3.45	$9,311
Net interest rate spread			2.58	$10,117				2.55	$10,062				2.25	$8,783
Non-interest bearing deposits		$139,238					$141,300					$127,953
Other liabilities		$4,947					$8,747					$8,109
Shareholders’ equity		$126,897					$122,335					$104,688
Total liabilities and shareholders’ equity		$1,365,948					$1,376,052					$1,309,545
Cost of funds			2.79					2.76					3.08
Net interest margin			3.13					3.10					2.82
*The information is preliminary, unaudited and based on company data available at the time of presentation.
Yield Table Assumptions – Average loan balances are inclusive of nonperforming loans. Net interest spread is calculated as the yields realized on interest-bearing assets less the rates paid on interest-bearing liabilities. Changes in net interest income are attributed to either changes in average balances (volume change) or changes in average rates (rate change) for earning assets and sources of funds on which interest is received or paid. Volume change is calculated as change in volume times the previous rate while rate change is change in rate times the previous volume. Changes not due solely to volume or rate changes are allocated to volume change and rate change in proportion to the relationship of the absolute dollar amounts of the change in each category.

Truxton Corporation Yield Tables For The Periods Indicated (000’s) (Unaudited)
The following table sets forth the amount of our average balances, interest income or interest expense for each category of interest earning assets and interest-bearing liabilities and the average interest rate for interest earning assets and interest-bearing liabilities, net interest spread and net interest margin for the periods indicated below:
		Nine Months Ended				Nine Months Ended
		September 30, 2026*				September 30, 2025*
		Average Balances	Rates / Yields (%)	Interest Income / Expense		Average Balances	Rates / Yields (%)	Interest Income / Expense
Earning assets
Loans		$809,801	6.07	$36,738		$695,162	6.13	$31,705
Loan fees		$0	0.12	$725		$0	0.13	$867
Loans, including fees		$809,801	6.19	$37,463		$695,162	6.26	$32,572
Taxable securities		$436,437	4.95	$16,218		$394,960	4.86	$14,389
Tax-exempt securities		$66,707	5.42	$1,816		$47,251	4.54	$1,077
Interest-bearing deposits in other financial institutions		$22,890	3.72	$637		$35,788	4.33	$1,159
Federal funds sold		$5,189	3.65	$143		$3,128	4.18	$99
Total earning assets		$1,341,024	5.69	$56,277		$1,176,289	5.66	$49,296
Noninterest earning assets
Allowance for credit losses		($7,943)				($6,691)
Cash and due from financial institutions		$6,231				$9,132
Premises and equipment		$2,740				$3,157
Accrued interest receivable		$4,461				$4,033
Other assets		$43,001				$50,825
Unrealized loss on investment securities		($11,466)				($17,598)
Total assets		$1,378,048				$1,219,147
Interest-bearing liabilities
Interest-bearing demand		$386,458	2.83	$8,169		$338,396	3.09	$7,821
Savings and money market		$272,986	2.47	$5,036		$249,101	2.70	$5,033
Time deposits – retail		$10,130	3.20	$242		$12,547	3.38	$317
Time deposits – wholesale		$363,330	3.79	$10,286		$314,845	4.19	$9,857
Total interest-bearing deposits		$1,032,904	3.07	$23,733		$914,889	3.37	$23,028
Subordinated debentures and other		$0	0.00	$0		$14,319	5.20	$565
Short-term borrowings		$7,601	1.88	$108		$8,727	4.31	$188
Long-term borrowings		$64,839	3.74	$1,838		$32,525	4.15	$1,024
Total borrowed funds		$72,440	3.54	$1,946		$55,571	4.22	$1,777
Total interest-bearing liabilities		$1,105,344	3.10	$25,679		$970,460	3.41	$24,805
Net interest rate spread			2.59	$30,598			2.24	$24,491
Non-interest bearing deposits		$142,661				$130,989
Other liabilities		$7,104				$5,552
Shareholders’ equity		$122,939				$112,146
Total liabilities and shareholders’ equity		$1,378,048				$1,219,147
Cost of funds			2.75				3.01
Net interest margin			3.14				2.84
*The information is preliminary, unaudited and based on company data available at the time of presentation.
Yield Table Assumptions – Average loan balances are inclusive of nonperforming loans. Net interest spread is calculated as the yields realized on interest-bearing assets less the rates paid on interest-bearing liabilities. Changes in net interest income are attributed to either changes in average balances (volume change) or changes in average rates (rate change) for earning assets and sources of funds on which interest is received or paid. Volume change is calculated as change in volume times the previous rate while rate change is change in rate times the previous volume. Changes not due solely to volume or rate changes are allocated to volume change and rate change in proportion to the relationship of the absolute dollar amounts of the change in each category.